Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Reckitt on track to deliver FY targets as Q1 LFL sales rise

(Sharecast News) - Consumer goods giant Reckitt Benckiser said on Wednesday that it was on track to deliver its full-year revenue and profit targets as it posted a rise in first-quarter like-for-like net sales. In an update for the three months to the end of March, the Dettol and Lysol maker said LFL net revenue grew 1.5% to £3.7bn, with a volume decline of 0.5% and price/mix growth of 2%.

The hygiene segment saw LFL net revenue growth of 7.1%, with broad-based volume growth across Finish, Lysol, Harpic and Vanish.

In the health unit, LFL net revenues rose 1%. Reckitt pointed to strong volume growth across Intimate Wellness, non-seasonal over-the-counter brands, VMS and Dettol. This was offset by the expected lapping of prior year retailer inventory rebuild in seasonal OTC products.

In nutrition, however, LFL net revenue fell 9.9%.

Reckitt reiterated its 2024 guidance for LFL net revenue growth of between 2% and 4% for the group. It also continues to expect mid-single-digit growth for the health and hygiene portfolios and a mid to high-single-digit decline for the nutrition business.

Chief executive Kris Licht said: "We have delivered a good first quarter. Following a period of price-led growth, we are now returning to a more balanced contribution from price, mix and volume. We grew volumes in many of our powerbrands in the quarter, including Lysol, Dettol, Durex and Finish, as well as our non-seasonal OTC portfolio.

"In addition, we continue to benefit from carryover pricing and consumers trading up to our premium innovations.

"The net revenue performance in the quarter is in line with our expectations. Hygiene delivered broad-based growth. Health saw good growth across many brands, reduced by a tough comparator in our cold & flu OTC brands. Nutrition continues to normalise in the US as expected, and we have maintained our value market share leadership."

At 1045 BST, the shares were up 5.1% at 4,468p.

Share this article

Related Sharecast Articles

Kefi shares pop on official launch of Tulu Kapi
(Sharecast News) - Kefi Gold and Copper officially launched the Tulu Kapi Gold Mines (TKGM) project in Ethiopia on Monday.
Sajid Javid reportedly in talks to join Shein ahead of London IPO
(Sharecast News) - Singapore-based fast fashion retailer Shein has reportedly approached the former chancellor Sajid Javid about joining the company ahead of its rumoured listing on the London Stock Exchange.
Bradda Head reaches settlement over fraudulent payment
(Sharecast News) - North America-focussed lithium developer Bradda Head announced on Monday that it has reached a settlement agreement over the fraudulent payment initially reported on 29 March 2022.
SDI Group set to end year in line with forecasts
(Sharecast News) - Scientific digital imaging, sensing and control technology company SDI Group said in a trading update on Monday that, pending its final accounts and audit, it expected to report revenue of £65.9m for the year, in line with current market expectations, but slightly down from £67.6m in 2023.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.